Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Thomas Wessel


  • Evp, Head Of R&d at Relmada Therapeutics Inc. (RLMD), 2020-03-16
  • Chief Medical Officer at Flex Pharma Inc. (FLKS), 2018-01-19
  • Chief Medical Officer at Acorda Therapeutics Inc (ACOR), 2011-03-07
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
FLKS $9.13 8,000 Officer 57,064 2016-03-14 Filing
FLKS $7.15 12,000 Officer 49,064 2016-03-11 Filing